<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-445
Date of Submission: 2024-09-30

This report was submitted by a Physician from Becker-Ayala Medical Center concerning patient ANON-PX-4647. The subject is a 51-year-old female with a significant medical history including atrial fibrillation, seasonal allergies, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intravenous route at a dosage of 287mg, initiated on 2024-08-24 for Hypothyroidism and discontinued on 2024-09-10; Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 47mg, initiated on 2024-08-24 for Gastroesophageal reflux disease and discontinued on 2024-09-10.

On approximately 2024-09-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Maculopapular Rash. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed federal and advised across. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed firm and advised yard. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Bar specific particular program skin discuss person give. Student along concern nor enter across.</data>
report_id: ADR-2024-445
report_date: '2024-09-30'
patient_details:
  patient_id: ANON-PX-4647
  gender: Female
  relevant_history:
  - atrial fibrillation
  - seasonal allergies
  - migraines
  age_at_reaction: 51
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 287mg
  route_of_administration: Intravenous
  start_date: '2024-08-24'
  indication_for_use: Hypothyroidism
  end_date: '2024-09-10'
- drug_name: Omeprazole
  dosage: 47mg
  route_of_administration: Intravenous
  start_date: '2024-08-24'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2024-09-10'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2024-09-10'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed federal and advised across.
- symptom_name: Maculopapular Rash
  onset_date: '2024-09-10'
  severity: Mild
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed firm and advised yard.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Becker-Ayala Medical Center
reporter_type: Physician
notes: Bar specific particular program skin discuss person give. Student along concern
  nor enter across.
